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Abstract
Reade et al. studied 20 agitated intubated patients in a pilot open-
label trial comparing the efficacy of dexmedetomidine versus
haloperidol in facilitating extubation. While the study design had
limitations, which are outlined by the authors themselves in the
paper published in this issue of Critical Care, the study
demonstrated an impressive reduction in time to extubation and
length of stay. Dexmedetomidine is a promising sedative agent that
acts via α2-receptors and has been shown to decrease prevalence
and duration of delirium in mechanically ventilated patients.
Haloperidol is the recommended and standard drug to treat
delirium, largely based on large case series and reports. Delirium is
a common, underdiagnosed and serious problem in intensive care
unit patients. Agitated delirious patients are at risk of immediate
adverse events as well as prolonged respiratory support. All
delirious patients are at risk of poor cognitive outcomes. Further
research is needed into the pharmacological management of
delirium, including the use of dexmedetomidine in the management
of agitation and the clinical efficacy of haloperidol.
As reported in this issue of Critical Care, Reade and
colleagues [1] have completed a pilot open-label trial com-
paring the efficacy of haloperidol with dexmedetomidine in
the treatment of ventilated patients with agitation. This is an
important contribution to the literature on delirium manage-
ment despite the limitations of what is essentially a pragmatic
feasibility study. Agitation leads to adverse events such as
accidental extubation, removal of arterial and central lines and
injury. The current delirium treatment used by the majority of
intensivists worldwide is haloperidol. With agitation, clinicians
often also use benzodiazepines for rapid control. This may
result in continuing or starting respiratory support for over-
sedation. Also, benzodiazepines and physical restraints are
deliriogenic. A recent Cochrane review concluded that
benzodiazepines cannot be recommended for the control of
this condition [2].
Dexmedetomidine is a highly selective α2-receptor agonist
that has been available in the US since 1999 as a short-term
sedative in the intensive care unit (ICU). It has an affinity for
the  α2-receptor that is eight times higher than that of
clonidine and a half-life of 2 hours. It is clinically effective, has
opiate-sparing properties and is well tolerated. It is not yet
available for general use in Europe. Reade and colleagues
studied 20 intubated agitated patients and demonstrated
impressive decreases in time to extubation and ICU length of
stay in patients on dexmedetomidine as opposed to
haloperidol. There are case reports regarding the successful
use of dexmedetomidine in agitated patients with withdrawal
syndromes and facilitating extubation in 13 of 20 agitated
patients difficult to wean [3,4]. Conversely, a retrospective
assessment of 40 patients found transitioning to dexmedeto-
midine to be associated with increased agitation and pain.
Five patients self-extubated and four of these needed
emergency reintubation [5].
Delirium is common, life-threatening and largely ignored in
most ICUs. In fact, the majority of patients with delirium are
hypoactive, are quiet and lethargic, or present with a mixed
hypo/hyperactive variant [6]. If clinicians do not use a simple
tool to screen for diagnostic features of delirium, they are
likely to miss it 70% of the time [7]. The incidence in a UK
critical care unit is documented as two out of three
mechanically ventilated patients [8]. The issue regarding the
pharmacological management of delirium, agitated or
otherwise, is the lack of evidence. Although haloperidol has
been used on hundreds of thousands of patients since 1950
and is the drug of choice in all delirium guidelines, this is
solely on the basis of case series or case reports rather than
any robust clinical effectiveness trials. Regardless, most
patients with delirium are untreated because it is usually
undiagnosed. This is frustrating for those of us who are clear
about the impact of delirium. The undeniable association
between delirium and long-term cognitive impairment alone
should prompt us to take notice [9]. Discharging patients so
they can spend the rest of their lives in a nursing home
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or struggling to remember names goes against all we are
trying to achieve. While this study is small and unblinded and
lacks objective endpoints, it is welcome not because it shows
that dexmedetomidine is effective in the treatment of agitated
delirium (although the findings suggest it may be), but
because it shows that haloperidol may not be.
Delirium has bad outcomes. Hyperactive delirious patients
are often violent and remain days longer on sedation and
ventilated due to agitation. Dexmedetomidine is a good
choice for investigation. But pure hyperactive delirium is just
the tip of the iceberg; many more patients are quietly
delirious. We do not know whether treating delirium will
improve outcomes; the study has not been done. We do not
know whether haloperidol decreases mortality as hypothe-
sised by Milbrandt and colleagues [10] or increases mortality
as retrospective cohort studies in demented patients have
suggested [11]. Two other Cochrane reviews into delirium
conclude that more trials are urgently needed [12,13]. Now
clinicians need to decide whether to implement delirium
screening as recommended and how to manage hypoactive
delirium in their patients. Delirium screening resources are
available on ICU delirium information websites [14].
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